- Home
- SLGL vs CNTB Comparison
SLGL vs CNTB Comparison
Compare SLGL & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLGL | CNTB |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.7M | 128.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SLGL | CNTB |
|---|---|---|
| Price | $71.94 | $2.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $110.00 | $8.50 |
| AVG Volume (30 Days) | 29.6K | ★ 92.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $122.71 | N/A |
| Revenue Next Year | N/A | $24,739.01 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.02 | $0.51 |
| 52 Week High | $76.80 | $3.28 |
Technical Indicators
Market Signals| Indicator | SLGL | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 64.66 | 62.59 |
| Support Level | $62.08 | $2.23 |
| Resistance Level | $76.80 | $2.70 |
| Average True Range (ATR) | 6.90 | 0.27 |
| MACD | 0.42 | 0.04 |
| Stochastic Oscillator | 81.33 | 79.79 |
Price Performance
Historical ComparisonAbout SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.